Biocept Inc. (NASDAQ: BIOC) announced today that it has entered a provider agreement with Alliance Global FZ, LLC to market and distribute Biocept’s Target Selector liquid biopsy tests in the United Arab Emirates, and select countries in the Middle East, North & Sub-Saharan Africa, and Southeast Asia region.

"We are pleased to partner with Alliance Global to offer patients diagnosed with cancer access to our patented liquid biopsy testing," said Michael Nall, President and CEO of Biocept.

All diagnostic testing services under the agreement will be done at Biocept’s San Diego based CLIA-certified laboratory with Alliance Global taking responsibility for sales, marketing, distribution and reimbursement of the Company’s liquid biopsy platform.

"A major focus will be to use Biocept's testing services to support global biopharmaceutical companies in qualifying patients for their targeted therapies. We feel that Biocept's Target Selector™ assays with industry-leading sensitivity are uniquely suited for this application,"

The Company has not disclosed any additional terms of the agreement.

Following the agreement announcement, Biocept shares soared over 70%.